Other than the fact that prostate-specific antigen (PSA) screening is a simple blood test, little else about this cornerstone of prostate cancer screening is simple. That includes the question of whether there are normal PSA levels by age. Generally, your risk of having prostate cancer increases along with your PSA
Tag: high grade prostate cancer
Prostate cancer is the second-most-common cancer in men (after skin cancer) and the second-most-common cause of cancer-related death in men (after lung cancer). Latest data from the American Cancer Society: One in nine men will be diagnosed with prostate cancer in their lifetime, and one in 41 will die from
It’s well known that the prostate-specific antigen (PSA) test used to screen for prostate cancer is imprecise. Elevations in PSA may signal prostate cancer, but they also may be due to nonmalignant prostate conditions.
Further complicating the screening process is that several medications and a number of other modifiable factors may
Prostate cancer is the second-most-common cancer in men (after skin cancer) and the second-most-common cause of cancer-related death in men (after lung cancer). One in seven men will be diagnosed with prostate cancer in their lifetime.
To keep things in perspective, however, it is also one of the most survivable cancers:
The glandular cells of the prostate play an important role in reproduction, producing the fluids that help make up semen. These tiny cells also serve as the birthplace for nearly all prostate cancers. Genes in these cells slowly mutate, leading to the formation of abnormal cells. The cells proliferate and
The prostate-specific antigen (PSA) blood test remains central to prostate cancer screening and, at the same time, at the center of considerable controversy. While proponents cite data supporting the test as a way to reduce the risk of dying from prostate cancer, critics point to the chain of events that
Long-term testosterone replacement therapy is not associated with a greater risk of high-grade prostate cancer, according to a study published in the December 2015 issue of the Journal of Urology. Researchers reviewed data on more than 52,000 male Medicare recipients diagnosed with prostate cancer between 2001 and 2006. In the